AMENDMENTS TO THE CLAIMS

Please amend the claims as shown below without prejudice or disclaimer. This listing of the claims replaces all prior versions and listings.

1-87. Cancelled

- 88. (New) A pharmaceutical composition comprising a sequestering subunit comprising naltrexone and a blocking agent that substantially prevents release of the naltrexone from the sequestering subunit, the sequestering subunit being overcoated with an opioid agonist in releasable form.
- 89. (New) The pharmaceutical composition of claim 88 wherein the blocking agent prevents the release of at least about 99% of the naltrexone from the sequestering subunit in the gastrointestinal tract for at least about 12 hours.
- 90. (New) The pharmaceutical composition of claim 88 wherein the blocking agent prevents the release of at least about 95% of the naltrexone from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours.
- 91. (New) The pharmaceutical composition of claim 88 wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, oxycodone, and hydrocodone.
- 92. (New) The pharmaceutical composition of claim 91 wherein the opioid agonist is morphine.
- 93. (New) The pharmaceutical composition of claim 88 wherein the blocking agent comprises a surfactant.
- 94. (New) The pharmaceutical composition of claim 93 wherein the surfactant is sodium lauryl sulphate.
- 95. (New) The pharmaceutical composition of claim 88 wherein the blocking agent comprises Eudragit RS PO and sodium lauryl sulphate, the blocking agent prevents the release of at least about 99% of the naltrexone from the sequestering subunit in the gastrointestinal tract for at least about 12 hours, the blocking agent prevents the release of at least about 95% of the naltrexone from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours, and the opioid agonist is morphine.
- 96. (New) A pharmaceutical composition comprising:

- a. a sequestering subunit comprising:
 - i. a naltrexone core comprising naltrexone on a substrate; and,
 - ii. a coating comprising a hydrophobic material and a surfactant covering the naltrexone core; and.
- b. an overcoat comprising an opioid agonist covering the sequestering subunit.
- 97. (New) The pharmaceutical composition of claim 96 wherein the substrate is a spheroid or a bead.
- 98. (New) The pharmaceutical composition of claim 96 wherein the surfactant is sodium lauryl sulphate.
- 99. (New) The pharmaceutical composition of claim 96 wherein the coating prevents the release of at least about 99% of the naltrexone from the sequestering subunit in the gastrointestinal tract for at least about 12 hours.
- 100. (New) The pharmaceutical composition of claim 96 wherein the coating prevents the release of at least about 95% of the naltrexone from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours.
- 101. (New) The pharmaceutical composition of claim 96 wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, oxycodone, and hydrocodone.
- 102. (New) The pharmaceutical composition of claim 101 wherein the opioid agonist is morphine.
- 103. (New) The pharmaceutical composition of claim 96 wherein the blocking agent comprises a surfactant.
- 104 (New) The pharmaceutical composition of claim 103 wherein the surfactant is sodium lauryl sulphate.
- 105. (New) The pharmaceutical composition of claim 96 wherein the blocking agent comprises Eudragit RS PO and sodium lauryl sulphate, the blocking agent prevents the release of at least about 99% of the naltrexone from the sequestering subunit in the gastrointestinal tract for at least about 12 hours, the blocking agent prevents the release of at least about 95% of the naltrexone from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours, and the opioid agonist is morphine.

- 106. (New) A sequestering subunit comprising naltrexone and a blocking agent comprising a surfactant wherein the blocking agent prevents the release of at least about 99% of the naltrexone from the sequestering subunit in the gastrointestinal tract for at least about 12 hours and prevents the release of at least about 95% of the naltrexone from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours.
- 107 (New) The sequestering subunit of claim 106 wherein the surfactant is sodium lauryl sulphate.
- 108. (New) The sequestering subunit of claim 106 wherein the blocking agent comprises the surfactant sodium lauryl sulphate and Eudragit RS PO.